10:05:25 EDT Mon 15 Apr 2024
Enter Symbol
or Name
USA
CA



Ventripoint Diagnostics Ltd (2)
Symbol VPT
Shares Issued 157,182,655
Close 2024-02-13 C$ 0.305
Market Cap C$ 47,940,710
Recent Sedar Documents

Ventripoint appoints Hendriks as partnership executive

2024-02-13 13:27 ET - News Release

Mr. Hugh MacNaught reports

VENTRIPOINT WELCOMES BART HENDRIKS AS NEW STRATEGIC PARTNERSHIPS EXECUTIVE TO ACCELERATE EUROPEAN AND GLOBAL SALES

Ventripoint Diagnostics Ltd. has welcomed Bart Hendriks as the company's new strategic partnership executive to accelerate adoption of Ventripoint's AI-powered (artificial intelligence) heart-scanning technology by hospitals and clinics in Europe and around the world.

A seasoned professional in the medtech (medical technology) artificial intelligence field, Mr. Hendriks brings a wealth of experience from his tenure in various leadership capacities, including chief executive officer and founder of innovative ventures in medical technology, diagnostics and AI-driven clinical applications.

Based in the Netherlands, Mr. Hendriks will focus on expanding European and global sales of Ventripoint's technology, which analyzes ultrasound scans and provides MRI-quality (magnetic resonance imaging) measurements of the heart at the fraction of the cost and time and trauma of MRIs.

"Bart has excelled in global sales and marketing management, strategic partner development, change management and has shown adeptness in mergers and acquisitions, deal structuring, negotiations, and team leadership," said Hugh MacNaught, Ventripoint's interim chief executive officer. "Our focus is now commercialization of Ventripoint's technology. Bart's track record includes successfully closing multiple funding rounds, securing strategic contracts and driving substantial revenue growth across different organizations. "

Mr. Hendriks's role begins immediately.

Mr. Hendriks added: "Ventripoint's technology is unique, offering a revolutionary mix of precision, efficiency and user friendliness in cardiac diagnostics using artificial intelligence. This cutting-edge tool is set to alter the paradigm of heart health management, making cardiac scans more accessible and effective for patients across the globe, and offers a portable, inexpensive alternative to MRIs that takes only minutes."

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.